Login to Your Account

Pharma: Clinic Roundup

Monday, July 29, 2013
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, unblinded the ELM-PC 5 Phase III study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration-resistant prostate cancer that had progressed during or following chemotherapy based on the recommendation of the independent data monitoring committee.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription